MUC1 and cancer: The provocative findings that the MUC1-N TRs are aberrantly under- or unglycosylated in cancer cells as compared to that in normal epithelia [113,114] invoked the possibility that vaccines and other immunotherapeutic approaches directed against the TRs could be developed to selectively treat human cancers.